Inicio・Lista de Acciones・ImmunityBio Inc

ImmunityBio Inc

Cerrado

SectorSanidad

7.31 0.69

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

7.18

Máximo

7.48

Métricas clave
By Trading Economics
Ingresos	-571M -633M
Ventas	5.9M 44M
BPA	-0.08
Margen de beneficios	-1,431.439
Empleados	684
EBITDA	-569M -600M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+79.31% upside

Dividendos
By Acuity
Próximas Ganancias	2 nov 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-293M 7.5B
Apertura anterior	6.62
Cierre anterior	7.31

Noticias sobre sentimiento de mercado

By Acuity

50%

156 / 340 Clasificación en Healthcare

ImmunityBio Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

5 ago 2026, 19:26 UTC

Immunitybio Inc's shares are higher today amid positive market sentiment. The stock is recovering from earlier weakness despite remaining below its 20-day moving average.

4 ago 2026, 23:46 UTC

Immunitybio Inc. shares are trading roughly flat in after-market hours. The asset remains significantly below its 20-day moving average.

3 ago 2026, 23:21 UTC

Immunitybio Inc shares rose in after-market trading, settling higher since Monday's close. The stock remains below its 20-day moving average.

1 ago 2026, 00:02 UTC

Immunitybio Inc shares are higher in after-market trading, reflecting a notable increase since Friday's close amid broader market dynamics.

31 jul 2026, 23:06 UTC

Immunitybio Inc's shares are higher in after-market trading, though no specific news was identified to explain the movement. The stock remains below its 20-day moving average.

30 jul 2026, 19:29 UTC

Immunitybio Inc is trading higher, recovering from an earlier drop. The stock has rebounded significantly since Wednesday's close, despite six consecutive lower daily closes.

29 jul 2026, 23:41 UTC

News

ImmunityBio receives UAE marketing authorization for ANKTIVA®, expanding its reach to 34 countries. Shares are trading higher in after-market hours following the announcement.

28 jul 2026, 20:06 UTC

News

ImmunityBio Inc is under investigation for potential wrongdoing, contributing to its decline today. Shares remain lower since Monday's close, marking six consecutive sessions of losses.

27 jul 2026, 19:16 UTC

Immunitybio Inc. shares are lower, continuing a four-session decline amid broader market pressures and a significant drop in oil prices.

24 jul 2026, 23:06 UTC

Immunitybio Inc shares are higher in after-market hours following Friday's close, settling with a cumulative increase after earlier gains. No specific news was identified.

23 jul 2026, 09:16 UTC

Immunitybio Inc shares are higher in pre-market hours, continuing an upward trend since Wednesday. This movement occurs amid broader market pressures from disappointing tech earnings.

22 jul 2026, 19:11 UTC

Immunitybio Inc's shares are lower today, diverging from recent gains. The stock is seeing unusually high trading volume amid rising crude oil prices.

21 jul 2026, 18:06 UTC

Immunitybio Inc is trading higher during Tuesday's session amid positive market sentiment. No specific company news was identified to explain the movement.

20 jul 2026, 23:46 UTC

Immunitybio Inc. shares are higher in after-market trading, reflecting routine activity. The stock remains below its 20-day moving average.

Comparación entre iguales

Cambio de precio

ImmunityBio Inc previsión

Precio Objetivo

By TipRanks

79.31% repunte

Estimación a 12 Meses

Media 13 USD 79.31%

Máximo 15 USD

Mínimo 12 USD

De acuerdo con 3 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para ImmunityBio Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

3 ratings

Comprar

Mantener

Vender

De acuerdo con 3 analistas que ofrecen calificaciones bursátiles a para ImmunityBio Inc Dist en los últimos 3 meses.

Sentimiento

By Acuity

156 / 340 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de ImmunityBio Inc

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.